VI-TWEL Drug Patent Profile
Which patents cover Vi-twel, and when can generic versions of Vi-twel launch?
Vi-twel is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in VI-TWEL is cyanocobalamin. There is one drug master file entry for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cyanocobalamin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vi-twel
A generic version of VI-TWEL was approved as cyanocobalamin by PADAGIS ISRAEL on September 9th, 2020.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VI-TWEL?
- What are the global sales for VI-TWEL?
- What is Average Wholesale Price for VI-TWEL?
Summary for VI-TWEL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| DailyMed Link: | VI-TWEL at DailyMed |
US Patents and Regulatory Information for VI-TWEL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | VI-TWEL | cyanocobalamin | INJECTABLE;INJECTION | 007012-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
